Acadia CEO on the Fight Against Rare Diseases
January 14, 2026
7 min
Full
5,103 of 5,353
January 14, 2026
Acadia CEO on the Fight Against Rare Diseases
0:00 / 7:00
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Bloomberg Originals Episodes Around January 14, 2026
Episode 5,103 of 5,353 — walk the feed in the order it was published.
7:00This episodeAcadia CEO on the Fight Against Rare Diseases
Summary
<p>Acadia Pharmaceuticals, a leader in neuroscience and rare disease, is working to advance next-generation therapies. The company's commercial portfolio already includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. Acadia is also developing the next wave of therapeutic advancements with a pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. <br /><br />Catherine Owen Adams, the CEO of Acadia, discusses her firm's commitment to turning scientific promise into meaningful innovation that can help make a difference for underserved neurological and rare disease communities around the world. Catherine speaks with Tim Stenovec and Emily Graffeo on Bloomberg Businessweek Daily.</p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
Episode details and artwork are published by the show’s own feed. Sentinel plays short cited excerpts and links every episode back to its publisher.